505767441 11/11/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5814257

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
BIN LIU	10/29/2019
YANG SU	11/04/2019
SCOTT BIDLINGMAIER	10/30/2019
CHRISTOPHER BEHRENS	11/04/2019
NAMKYUNG LEE	11/01/2019

RECEIVING PARTY DATA

Name:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Street Address:	1111 FRANKLIN STREET, TWELFTH FLOOR
City:	OAKLAND
State/Country:	CALIFORNIA
Postal Code:	94607-5200

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	15508059

CORRESPONDENCE DATA

Fax Number: (510)663-0920

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 510-663-1100

Email: SJoshi@wavsip.com

Correspondent Name: WEAVER AUSTIN VILLENEUVE & SAMPSON LLP

Address Line 1: P.O. BOX 70250

Address Line 4: OAKLAND, CALIFORNIA 94612-0250

ATTORNEY DOCKET NUMBER:	UCSFP037US/SF-2014-106-2	
NAME OF SUBMITTER:	SWAPNALI JOSHI	
SIGNATURE:	/Swapnali Joshi/	
DATE SIGNED:	11/11/2019	

Total Attachments: 5

source=UCSFP037US_Executed_Assignment_allInvts_ackg#page1.tif

PATENT 505767441 REEL: 050974 FRAME: 0842

source=UCSFP037US_Executed_Assignment_allInvts_ackg#page2.tif source=UCSFP037US_Executed_Assignment_allInvts_ackg#page3.tif source=UCSFP037US_Executed_Assignment_allInvts_ackg#page4.tif source=UCSFP037US_Executed_Assignment_allInvts_ackg#page5.tif

Attorney Docket No. <u>UCSFP037US</u> UCSF Case No.:SF2014-106-2

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

1. Bin Liu 2. Yang Su 3. Scott Bidlingmaier 4. Christopher Behrens 5. Namkyung Lee

hereby sells, assigns and transfers to ASSIGNEE, The Regents of the University of California, a California Corporation, having its statewide administrative offices located 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS

and which is found in

- (a) X U.S. application serial no. 15/508,059 filed on March 1, 2017
- (b) X PCT patent application serial no. PCT/US2015/049492 filed on September 10, 2015

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(a) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent and all rights under all International Conventions for the Protection of Industrial Property;

ASSIGNOR(S) hereby agrees that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further agrees that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, post grant review, inter partes review, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

AND the <u>ASSIGNOR(S)</u> requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

executed this		Signature of Inventor(s)	
1) <u>29</u> day of <u>Oct</u> , 20 <u>1</u> 9	Bin Liu:	Bin Liu	Digitally signed by Bin Liu ON: cm-Bin Liu, o-IUCSF, ou, email-bin Ju@ucsf.edu, c-US Doier 2019.10.29 12:2044-08:00*
2)day of, 20	Yang Su:		
3)day of, 20	Scott Bidlingmaier:		
4)day of, 20	Christopher Behrens:		
5) day of, 20	Namkyung Lee:		
		/)	
Assignee hereby accepts this Assign	ment:	Reference	1010
Date: November 4, 2019		Tenya Foldman Senior Patent Prosecutio Innovation Ventures LLCSF	n Analysi

Attorney Docket No. <u>UCSFP037US</u> UCSF Case No.:<u>SF2014-106-2</u>

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

1. Bin Liu 2. Yang Su 3. Scott Bidlingmaier 4. Christopher Behrens 5. Namkyung Lee

hereby sells, assigns and transfers to ASSIGNEE, The Regents of the University of California, a California Corporation, having its statewide administrative offices located 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS

and which is found in

- (a) X U.S. application serial no. 15/508,059 filed on March 1, 2017
- (b) X PCT patent application serial no. PCT/US2015/049492 filed on September 10, 2015

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(a) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent and all rights under all International Conventions for the Protection of Industrial Property;

<u>ASSIGNOR(S)</u> hereby agrees that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further agrees that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, post grant review, inter partes review, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

AND the <u>ASSIGNOR(S)</u> requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

executed this		Signature of Inventor(s)
1) day of	Bin Liu:	
2) Aday of November, 20/9	Yang Su:	
3)day of 20	Scott Bidlingmaier	
4) day of, 20	Christopher Behrens:	
5) day of 20	Namkyung Lee:	
Assignee hereby accepts this Assignm	ient:	
Date: November 4, 2019	Tenya Fylich Senior Pate Innovation V	nt Prosecution Analyst

Attorney Docket No. <u>UCSFP037US</u> UCSF Case No.:<u>SF2014-106-2</u>

0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			
For good and valuable consideration,	the receipt of which is h	ereby acknowledged, ASS	(GNOR(S),
1 Rin Liu 2 Vano Su 3	Scott Ridlingmaier	4 Christopher Behrens	5. Namkyung Dec
hereby sells, assigns and transfers to Corporation, having its statewide adm 94607-5200, and the successors, assign the United States and its territorial postare disclosed in the invention entitled:	imistrative offices local	ACRICNEE all of	its right title and interest for
MACROPINOCYTOSING HUMAN	ANTI-CD46 ANTIBOI	DIES AND TARGETED C	ANCER THERAPEUTICS
and which is found in			
(a) X U.S. application serial no.			
(b) X PCT patent application se			
and any legal equivalent thereof in a tagget Patent to be obtained for said invention extension, conversion to 35 USC 111 Letters Patent and all rights under all In	on by the above applica (a) or substitute thereo	tion or any continuation, of and any reissue, reexan	livision, continuation-in-part, ination or extension of said
ASSIGNOR(S) hereby agrees that no a into which would conflict with this assi		ent or encumbrance has be	en or will be made or entered
ASSIGNOR(S) further agrees that ASS documents relating to said invention at ASSIGNOR and will testify as to the proceeding relating thereto and will propapers, instruments or affidavits require and said Letters Patent and said equivalence. An attorney of record is aut assignment the filing date and serial numerical said said serial numerical said said serial said serial said serial said serial said said serial said said serial said said said said said said said said	and said Letters Patent are same in any interference omptly execute and delived to apply for, obtain, malents thereof which malents thereof which malents and requested in the said of the	nd legal equivalents as may be, post grant review, into wer to ASSIGNEE or its le naintain, issue or enforce so ay be necessary or desiral by the execution of this a	y be known and accessible to r partes review, litigation, or gal representative any and all aid application, said invention ble to carry out the purposes
AND the <u>ASSIGNOR(S)</u> requests the United States and any reissue or extensi			
executed this		Signature of Inventor(s)	
1) day of, 20	Bin Liu:		·····
2)day of, 20	Yang Su:		
3)304 day of October , 2019	Scott Bidlingmaier:	Sott Bil	ini
4) day of, 20	Christopher Behrens:		
5)day of, 20	Namkyung Lee:		
Assignee hereby accepts this Assignn	nent:		
Date: November 4, 2019		Tenya Feldman Senior Patent Prosecutior Innovation Ventures UCSF	s Assalyss

Attorney Docket No. <u>UCSFP037US</u> UCSF Case No.:SF2014-106-2

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

1. Bin Liu 2. Yang Su 3. Scott Bidlingmaier 4. Christopher Behrens 5. Namkyung Lee

hereby sells, assigns and transfers to ASSIGNEE, The Regents of the University of California, a California Corporation, having its statewide administrative offices located 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPBUTICS

and which is found in

- (a) X U.S. application serial no. 15/508.059 filed on March 1, 2017
- (b) X PCT patent application serial no. PCT/US2015/049492 filed on September 10, 2015

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(a) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent and all rights under all International Conventions for the Protection of Industrial Property;

ASSIGNOR(S) hereby agrees that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further agrees that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, post grant review, inter partes review, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

AND the <u>ASSIGNOR(S)</u> requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

Assignee hereby accepts this Assignate: November 4, 2019	nent:	nya Fekiman nior Patent Prosecution Analysi
5)day of		
4) 4 day of <i>November</i> 2019	Christopher Behrens:	OL ML
3)day of	Scott Bidlingmaier:	
2) day of	Yang Su:	
1) day of20	Bin Liu:	
executed this		Signature of Inventor(s)

Attorney Docket No. <u>UCSFP037US</u> UCSF Case No.:SF2014-106-2

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

1. Bin Liu 2. Yang Su 3. Scott Bidlingmaier 4. Christopher Behrens 5. Namkyung Lee

hereby sells, assigns and transfers to ASSIGNEE. The Regents of the University of California, a California Corporation, having its statewide administrative offices located 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200, and the successors, assigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

MACROPINOCYTOSING HUMAN ANTI-CD46 ANTIBODIES AND TARGETED CANCER THERAPEUTICS

and which is found in

- (a) X U.S. application serial no. 15/508,059 filed on March 1, 2017
- (b) X PCT patent application serial no. PCT/US2015/049492 filed on September 10, 2015

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(a) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent and all rights under all International Conventions for the Protection of Industrial Property;

ASSIGNOR(S) hereby agrees that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further agrees that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, post grant review, inter partes review, litigation, or proceeding relating thereto and will promptly execute and deliver to ASSIGNEE or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue or enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

AND the <u>ASSIGNOR(S)</u> requests the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States and any reissue or extension thereof to the ASSIGNEE, The Regents of the University of California.

executed this	Signature of Inventor(s)
1) day of, 20 Bin Liu:	
2) day of, 20 Yang Su:	
3)day of, 20 Scott Bidlingmaier	
4) day of, 20 Christopher Behren	
5) 1 day of Now, 2019 Namkyung Lee:	
·	
Assignee hereby accepts this Assignment:	
Date: November 4, 2019	Tenya Feldman Senior Patent Prosecution Analyst Innovation Ventures - UCSF

PATENT REEL: 050974 FRAME: 0848

RECORDED: 11/11/2019